At LoQus23, our expert team is taking a structure-based approach to mismatch repair drug discovery, investigating small molecule drugs that could stop DNA instability and therefore slow neurodegeneration in Huntington’s disease, myotonic dystrophy type 1 and similar triplet repeat expansion diseases. Oral small molecule drugs have a strong track record in treating complex brain diseases and provide greater convenience for pa...
At LoQus23, our expert team is taking a structure-based approach to mismatch repair drug discovery, investigating small molecule drugs that could stop DNA instability and therefore slow neurodegeneration in Huntington’s disease, myotonic dystrophy type 1 and similar triplet repeat expansion diseases. Oral small molecule drugs have a strong track record in treating complex brain diseases and provide greater convenience for patients compared with other treatment approaches.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.